-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2016 to Q1 2023.
- Lineage Cell Therapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending March 31, 2023 was $138K, a 8% decline year-over-year.
- Lineage Cell Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $582K, a 12.2% decline from 2021.
- Lineage Cell Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2021 was $663K, a 19.4% decline from 2020.
- Lineage Cell Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2020 was $823K, a 17.9% decline from 2019.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)